Shares of Dermira Inc (NASDAQ:DERM) have been assigned an average rating of “Hold” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $43.20.

A number of analysts have issued reports on the stock. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Mizuho reissued a “buy” rating and issued a $43.00 price objective (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Leerink Swann reissued an “outperform” rating and issued a $41.00 price objective (down previously from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Guggenheim began coverage on shares of Dermira in a report on Tuesday, December 5th. They set a “buy” rating for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target (down previously from $46.00) on shares of Dermira in a report on Tuesday, November 7th.

In related news, CEO Thomas G. Wiggans sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $27.51, for a total transaction of $261,345.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,800 shares of company stock valued at $809,425. 13.30% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in DERM. Morgan Stanley increased its position in Dermira by 6.1% during the 1st quarter. Morgan Stanley now owns 76,638 shares of the biopharmaceutical company’s stock worth $2,614,000 after purchasing an additional 4,434 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Dermira in the 1st quarter valued at approximately $1,023,000. Schwab Charles Investment Management Inc. increased its position in Dermira by 5.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 113,236 shares of the biopharmaceutical company’s stock valued at $3,863,000 after acquiring an additional 5,850 shares during the period. Sei Investments Co. increased its position in Dermira by 4.0% in the 2nd quarter. Sei Investments Co. now owns 170,000 shares of the biopharmaceutical company’s stock valued at $4,954,000 after acquiring an additional 6,616 shares during the period. Finally, TD Asset Management Inc. increased its position in Dermira by 15.7% in the 2nd quarter. TD Asset Management Inc. now owns 42,815 shares of the biopharmaceutical company’s stock valued at $1,248,000 after acquiring an additional 5,800 shares during the period. Institutional investors and hedge funds own 99.54% of the company’s stock.

Shares of Dermira (DERM) opened at $27.51 on Thursday. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira has a twelve month low of $21.35 and a twelve month high of $38.75.

TRADEMARK VIOLATION NOTICE: “Dermira Inc (DERM) Given Average Recommendation of “Hold” by Brokerages” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/14/dermira-inc-derm-given-average-recommendation-of-hold-by-brokerages.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.